BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 26714427)

  • 1. Pediatric phase I trial of oral sorafenib and topotecan in refractory or recurrent pediatric solid malignancies.
    Reed DR; Mascarenhas L; Manning K; Hale GA; Goldberg J; Gill J; Sandler E; Isakoff MS; Smith T; Caracciolo J; Lush RM; Juan TH; Lee JK; Neuger AM; Sullivan DM
    Cancer Med; 2016 Feb; 5(2):294-303. PubMed ID: 26714427
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase I trial and pharmacokinetic study of sorafenib in children with refractory solid tumors or leukemias: a Children's Oncology Group Phase I Consortium report.
    Widemann BC; Kim A; Fox E; Baruchel S; Adamson PC; Ingle AM; Glade Bender J; Burke M; Weigel B; Stempak D; Balis FM; Blaney SM
    Clin Cancer Res; 2012 Nov; 18(21):6011-22. PubMed ID: 22962440
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Phase I Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Combination Therapy with Refametinib plus Sorafenib in Patients with Advanced Cancer.
    Adjei AA; Richards DA; El-Khoueiry A; Braiteh F; Becerra CH; Stephenson JJ; Hezel AF; Sherman M; Garbo L; Leffingwell DP; Iverson C; Miner JN; Shen Z; Yeh LT; Gunawan S; Wilson DM; Manhard KJ; Rajagopalan P; Krissel H; Clendeninn NJ
    Clin Cancer Res; 2016 May; 22(10):2368-76. PubMed ID: 26644411
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity.
    Azad NS; Posadas EM; Kwitkowski VE; Steinberg SM; Jain L; Annunziata CM; Minasian L; Sarosy G; Kotz HL; Premkumar A; Cao L; McNally D; Chow C; Chen HX; Wright JJ; Figg WD; Kohn EC
    J Clin Oncol; 2008 Aug; 26(22):3709-14. PubMed ID: 18669456
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase 1 study of simvastatin in combination with topotecan and cyclophosphamide in pediatric patients with relapsed and/or refractory solid and CNS tumors.
    Cash T; Jonus HC; Tsvetkova M; Beumer JH; Sadanand A; Lee JY; Henry CJ; Aguilera D; Harvey RD; Goldsmith KC
    Pediatr Blood Cancer; 2023 Aug; 70(8):e30405. PubMed ID: 37158620
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase 2 trial of sorafenib in children and young adults with refractory solid tumors: A report from the Children's Oncology Group.
    Kim A; Widemann BC; Krailo M; Jayaprakash N; Fox E; Weigel B; Blaney SM
    Pediatr Blood Cancer; 2015 Sep; 62(9):1562-6. PubMed ID: 26207356
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I dose-escalation study of plitidepsin in combination with sorafenib or gemcitabine in patients with refractory solid tumors or lymphomas.
    Aspeslagh S; Stein M; Bahleda R; Hollebecque A; Salles G; Gyan E; Fudio S; Extremera S; Alfaro V; Soto-Matos A; Soria JC
    Anticancer Drugs; 2017 Mar; 28(3):341-349. PubMed ID: 27977433
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I and pharmacokinetic study of topotecan administered orally once daily for 5 days for 2 consecutive weeks to pediatric patients with refractory solid tumors.
    Daw NC; Santana VM; Iacono LC; Furman WL; Hawkins DR; Houghton PJ; Panetta JC; Gajjar AJ; Stewart CF
    J Clin Oncol; 2004 Mar; 22(5):829-37. PubMed ID: 14990638
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I trial and pharmacokinetic study of sorafenib in children with neurofibromatosis type I and plexiform neurofibromas.
    Kim A; Dombi E; Tepas K; Fox E; Martin S; Wolters P; Balis FM; Jayaprakash N; Turkbey B; Muradyan N; Choyke PL; Reddy A; Korf B; Widemann BC
    Pediatr Blood Cancer; 2013 Mar; 60(3):396-401. PubMed ID: 22961690
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I and clinical pharmacology study of bevacizumab, sorafenib, and low-dose cyclophosphamide in children and young adults with refractory/recurrent solid tumors.
    Navid F; Baker SD; McCarville MB; Stewart CF; Billups CA; Wu J; Davidoff AM; Spunt SL; Furman WL; McGregor LM; Hu S; Panetta JC; Turner D; Fofana D; Reddick WE; Leung W; Santana VM
    Clin Cancer Res; 2013 Jan; 19(1):236-46. PubMed ID: 23143218
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I study of pemetrexed with sorafenib in advanced solid tumors.
    Poklepovic A; Gordon S; Shafer DA; Roberts JD; Bose P; Geyer CE; McGuire WP; Tombes MB; Shrader E; Strickler K; Quigley M; Wan W; Kmieciak M; Massey HD; Booth L; Moran RG; Dent P
    Oncotarget; 2016 Jul; 7(27):42625-42638. PubMed ID: 27213589
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase 1 study of sorafenib in combination with bortezomib in patients with advanced malignancies.
    Kumar SK; Jett J; Marks R; Richardson R; Quevedo F; Moynihan T; Croghan G; Markovic SN; Bible KC; Qin R; Tan A; Molina J; Kaufmann SH; Erlichman C; Adjei AA
    Invest New Drugs; 2013 Oct; 31(5):1201-6. PubMed ID: 23887852
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sorafenib plus topotecan versus placebo plus topotecan for platinum-resistant ovarian cancer (TRIAS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.
    Chekerov R; Hilpert F; Mahner S; El-Balat A; Harter P; De Gregorio N; Fridrich C; Markmann S; Potenberg J; Lorenz R; Oskay-Oezcelik G; Schmidt M; Krabisch P; Lueck HJ; Richter R; Braicu EI; du Bois A; Sehouli J; ;
    Lancet Oncol; 2018 Sep; 19(9):1247-1258. PubMed ID: 30100379
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase I study of the histone deacetylase (HDAC) inhibitor entinostat, in combination with sorafenib in patients with advanced solid tumors.
    Ngamphaiboon N; Dy GK; Ma WW; Zhao Y; Reungwetwattana T; DePaolo D; Ding Y; Brady W; Fetterly G; Adjei AA
    Invest New Drugs; 2015 Feb; 33(1):225-32. PubMed ID: 25371323
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I/II study of S-1 in combination with sorafenib for metastatic renal cell carcinoma.
    Naito S; Sakai H; Hashine K; Tomita Y; Shinohara N; Fujisawa M; Eto M; Ozono S; Akaza H
    Ann Oncol; 2015 Sep; 26(9):1871-1876. PubMed ID: 26117830
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase II trial of BAY 43-9006 (sorafenib) (NSC-724772) in patients with relapsing and resistant multiple myeloma: SWOG S0434.
    Srkalovic G; Hussein MA; Hoering A; Zonder JA; Popplewell LL; Trivedi H; Mazzoni S; Sexton R; Orlowski RZ; Barlogie B
    Cancer Med; 2014 Oct; 3(5):1275-83. PubMed ID: 24913924
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase I trial of concurrent sorafenib and stereotactic radiosurgery for patients with brain metastases.
    Arneson K; Mondschein J; Stavas M; Cmelak AJ; Attia A; Horn L; Niermann K; Puzanov I; Chakravarthy AB; Xia F
    J Neurooncol; 2017 Jun; 133(2):435-442. PubMed ID: 28488066
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I study to determine the safety and pharmacokinetics of the novel Raf kinase and VEGFR inhibitor BAY 43-9006, administered for 28 days on/7 days off in patients with advanced, refractory solid tumors.
    Moore M; Hirte HW; Siu L; Oza A; Hotte SJ; Petrenciuc O; Cihon F; Lathia C; Schwartz B
    Ann Oncol; 2005 Oct; 16(10):1688-94. PubMed ID: 16006586
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase 1 study of sorafenib and irinotecan in pediatric patients with relapsed or refractory solid tumors.
    Meany HJ; Widemann BC; Hinds PS; Bagatell R; Shusterman S; Stern E; Jayaprakash N; Peer CJ; Figg WD; Hall OM; Sissung TM; Kim A; Fox E; London WB; Rodriguez-Galindo C; Minturn JE; Dome JS
    Pediatr Blood Cancer; 2021 Nov; 68(11):e29282. PubMed ID: 34383370
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oral topotecan given once or twice daily for ten days: a phase I pharmacology study in adult patients with solid tumors.
    Gerrits CJ; Burris H; Schellens JH; Eckardt JR; Planting AS; van der Burg ME; Rodriguez GI; Loos WJ; van Beurden V; Hudson I; Fields S; Von Hoff DD; Verweij J
    Clin Cancer Res; 1998 May; 4(5):1153-8. PubMed ID: 9607572
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.